(Q44807139)

6 December 2017

title

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial (English)

1 reference

6 December 2017

main subject

phase II clinical trial

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Diana Giannarelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michele Maio

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Luana Calabro'

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Riccardo Danielli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Luciano Mutti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Ester Fonsatti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ornella Cutaia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Giovanni Amato

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Anna Maria Di Giacomo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Maresa Altomonte

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

11 September 2013

1 reference

Lancet Oncology Commission

6 December 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1104-1111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

Advances in malignant mesothelioma

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Multidisciplinary treatment of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Second-line treatment for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

What's the place of immunotherapy in malignant mesothelioma treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

New roads open up for implementing immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970381-4

7 January 2021

10.1016/S1470-2045(13)70381-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035405%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference